Cargando…

Early experience with remdesivir in SARS-CoV-2 pneumonia

At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durante-Mangoni, Emanuele, Andini, Roberto, Bertolino, Lorenzo, Mele, Ferruccio, Florio, Letizia Lucia, Murino, Patrizia, Corcione, Antonio, Zampino, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229436/ https://www.ncbi.nlm.nih.gov/pubmed/32418190 http://dx.doi.org/10.1007/s15010-020-01448-x

Ejemplares similares

Liver injury in remdesivir-treated COVID-19 patients
por: Zampino, Rosa, et al.
Publicado: (2020)

Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
por: Boccia, Filomena, et al.
Publicado: (2023)

Prognostic value of pro-adrenomedullin and copeptin in acute infective endocarditis
por: Zampino, Rosa, et al.
Publicado: (2021)

Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review
por: Ramadan, Mohammad Said, et al.
Publicado: (2021)

Infective endocarditis involving MitraClip(©) devices: a systematic literature review
por: Bertolino, Lorenzo, et al.
Publicado: (2023)

Long-Term Outcome of Infective Endocarditis Involving Cardiac Implantable Electronic Devices: Impact of Comorbidities and Lead Extraction
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2022)

Incidence, Risk Factors and Clinical Implications of Glucose Metabolic Changes after Heart Transplant
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2022)

Clinical Characteristics and Outcome of MDR/XDR Bacterial Infections in a Neuromuscular Semi-Intensive/Sub-Intensive Care Unit
por: Karruli, Arta, et al.
Publicado: (2022)

Cardiac complications during the active phase of COVID-19: review of the current evidence
por: Ramadan, Mohammad Said, et al.
Publicado: (2021)

Risk Factors and Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center Experience
por: Karruli, Arta, et al.
Publicado: (2021)

Does this patient have COVID-19? A practical guide for the internist
por: Bertolino, Lorenzo, et al.
Publicado: (2020)

Low rate of severe acute respiratory syndrome coronavirus 2 spread among health-care personnel using ordinary personal protection equipment in a medium-incidence setting
por: Durante-Mangoni, E., et al.
Publicado: (2020)

Dissecting the correlates of N-terminal prohormone brain natriuretic peptide in acute infective endocarditis
por: Bertolino, Lorenzo, et al.
Publicado: (2022)

Clinical Significance and Prognostic Value of Hemostasis Parameters in 337 Patients with Acute Infective Endocarditis
por: Zampino, Rosa, et al.
Publicado: (2021)

Prognostic Value of Decreased High-Density Lipoprotein Cholesterol Levels in Infective Endocarditis
por: Zampino, Rosa, et al.
Publicado: (2022)

Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia()
por: Cacho, Judit, et al.
Publicado: (2022)

Decoding Sepsis-Induced Disseminated Intravascular Coagulation: A Comprehensive Review of Existing and Emerging Therapies
por: Unar, Ahsanullah, et al.
Publicado: (2023)

Pathophysiology of Disseminated Intravascular Coagulation in Sepsis: A Clinically Focused Overview
por: Unar, Ahsanullah, et al.
Publicado: (2023)

Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
por: Ramadan, Mohammad Said, et al.
Publicado: (2021)

Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections
por: Giurazza, Roberto, et al.
Publicado: (2021)

Clinical significance of hyperhomocysteinemia in infective endocarditis: A case–control study
por: Iossa, Domenico, et al.
Publicado: (2016)

Anthropometric parameters and liver histology influence lipid metabolic changes in HCV chronic hepatitis on direct-acting antiviral treatment
por: Iossa, Domenico, et al.
Publicado: (2021)

The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study
por: Tumminia, Andrea, et al.
Publicado: (2022)

Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series
por: Patauner, Fabian, et al.
Publicado: (2022)

Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2022)

Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
por: Maraolo, Alberto Enrico, et al.
Publicado: (2022)

Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study
por: Fabrazzo, Michele, et al.
Publicado: (2020)

Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic
por: Poliseno, Mariacristina, et al.
Publicado: (2021)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Contre Sars-CoV-2, brequinar ou remdesivir ?
por: Manus, Jean-Marie
Publicado: (2021)

Remdesivir therapy associated with Bradycardia in SARS‐CoV2
por: Kumar, Sabina, et al.
Publicado: (2021)

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
por: Kokic, Goran, et al.
Publicado: (2021)

Enhanced Remdesivir Analogues to Target SARS-CoV-2
por: Majima, Ryuichi, et al.
Publicado: (2023)

Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
por: Ramadan, Mohammad Said, et al.
Publicado: (2022)

Early Stage Combination Treatment with Methylprednisolone Pulse and Remdesivir for Severe COVID-19 Pneumonia
por: Mastruzzo, Claudio, et al.
Publicado: (2023)

Arguments in favour of remdesivir for treating SARS-CoV-2 infections
por: Ko, Wen-Chien, et al.
Publicado: (2020)

Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2022)

Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection
por: Sanchez-Codez, Maria Isabel, et al.
Publicado: (2021)

507. Impact of Baricitinib on Outcomes in Patients Treated with Remdesivir and Dexamethasone for SARS-CoV-2 Pneumonia: A Retrospective Cohort Study
por: Dea, Lauren, et al.
Publicado: (2021)

505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v9al9ljj98drm8gssa5vj10tuq